Optimal route of misoprostol administration for the prevention of postpartum hemorrhage
Several RCTs have assessed various routes of misoprostol administration for the prevention of postpartum hemorrhage (PPH) due to uterine atony. A Cochrane review found that oral and sublingual routes improve patient outcomes of severe PPH and the need for blood transfusion. These findings are congruent with the new World Health Organization (WHO) recommendation to use misoprostol 600 mcg orally for the prevention of PPH if oxytocin, the first-line treatment for PPH, is not available or feasible.
Evidence Based Practice 18(1): 6